A6 Pharmaceuticals

A6 Pharmaceuticals is developing small molecule ARF6 inhibitors for a variety of conditions. Because ARF6 plays a critical role in pathologic protein trafficking, inhibition of ARF6, using our proprietary compounds, has been shown to be effective in animal models of acute lung injury/acute respiratory distress, certain types of cancer, diabetic retinopathy, age-related macular degeneration, and severe cerebral malaria.